Over the summer there has been much discussion on whether the UK remains the most competitive global base for life sciences businesses.
Some industry leaders have publicly reaffirmed their commitment to remaining UK-listed and headquartered, while others have hinted at the growing pull of the US, where investment levels and market opportunities continue to expand at pace.
The deadlock over NHS pricing is stirring these feelings up, and a resolution is becoming critical, as there is concern that pharma and life sciences businesses could consider pivoting their operations – and potentially headquarters elsewhere – which would be a major blow for one of the UK’s most dynamic and strategically important sectors.
The UK as a home for life sciences?
Despite some recent turbulence, the UK remains a fantastic home for innovation, research, and growth in the life sciences sector. It is home to an exceptional research and academic base, a highly skilled workforce, and a healthcare system that provides unique opportunities for large-scale clinical research.
Government support for the industry has been consistent and substantial. Initiatives such as R&D tax relief the patent box regime, and an £86 billion R&D funding package announced earlier this year have helped many life sciences companies to compete on a global stage.
While public resources are not limitless, there is a clear commitment to ensuring businesses have the appropriate support and conditions to thrive.
The recent Life Sciences Sector Plan, further underlines this. Its goals include increasing business investment in research, development, and manufacturing; Removing bureaucratic delays that slow patient access to new medicines and technologies; Reducing regional disparities in access to treatments; and introducing low-friction procurement and contracting processes for medical technology.
These initiatives send a strong signal of intent that the UK aims to be the most attractive place in the world to develop and deploy new treatments.
Challenges to address
However, the UK cannot afford complacency, and there are grievances among the industry that ideally need to be resolved to ensure the UK remains an attractive place for life sciences businesses.
Top of the list is the ongoing dispute over NHS medicine rebates. Given the turbulence and concern over Trump tariffs and pharma supply chains, this dispute must be resolved as quickly as possible to provide clarity and avoid shaking the industry further.
The Government finds itself in a difficult position as on the one hand, it wants to stimulate economic growth, but on the other, it’s constrained by its pledge to not raise major taxes, by borrowing costs and ongoing pressure to cut spending.
However, this is an issue – unlike other recent global challenges – which is solely in the UK’s control and for which an agreement can be found without having to involve others.
While it’s understandable the Government does not want to concede too much income from NHS charges to the pharmaceutical businesses, the current stalemate situation cannot go on for much longer, otherwise it risks diminishing the global competitiveness of its life sciences sector.
Meanwhile, the Life Sciences Sector Plan has had a mixed response from the industry, with some dissatisfaction around the UK’s pricing regime which is seen by some to prioritise low costs over investing in innovation and securing access to the latest medicine.
Negotiations between Government and industry remain fractured, and a resolution does not appear to be imminent.
Alongside this, the industry is anticipating tariffs, although these don’t appear they will be as eye-wateringly high as they potentially could have been.
Businesses have also lost talent to the US over the last few years, and face increasing pressure from the US government to equalise global drug pricing. They will therefore be hoping for more support to mitigate these pressures.
Why the UK Still Matters
Despite the headwinds, the UK retains many unique advantages. Its research ecosystem is internationally respected, and the NHS provides a distinctive platform for clinical trials and real-world data gathering that few countries can match.
The regulatory environment is established, stable, and increasingly open to innovation, while the clusters of excellence across the “Golden Triangle” of Cambridge, Oxford, and London, alongside other regional hubs, create a thriving environment for collaboration between academia, healthcare providers, and industry.
These strengths are not easily replicated elsewhere. For businesses considering their long-term strategy, the UK continues to offer both resilience and opportunity.
What does the future hold?
Over the last few years, the UK has established itself as being at the forefront of the life sciences industry – for example the role that it played in developing Covid 19 vaccinations is testament to this. However, there are clearly issues that must be addressed to ensure it remains a leader.
No business location is perfect, and the UK will need to continue refining its policies to remain globally competitive. Easing pricing pressures, improving regulatory speed, and ensuring sustained investment in skills and infrastructure will all be key to keeping pace with international competition.
Equally, the sector’s long-term success will depend on maintaining a collaborative relationship between government, industry, and the NHS. It will be crucial to balance affordability for patients with fair returns for innovators.
If this balance can be struck, the UK can not only hold its ground against the pull of the US, but also solidify its status as a global leader in life sciences.